Clinical Trial Update: Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab in combination with ipilimumab for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED